Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exparel for Post-operative Pain in Septorhinoplasty
NCT06989866Phase 3Enrolling by invitation
- Sponsor
- Naval Medical Center Portsmouth
- Start
- Dec 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bupivacaine in postoperative pain (2 arms), sponsored by Naval Medical Center Portsmouth. Primary endpoint: Use of Opiate Pain Medications After Rhinoplasty at 1 week. Started Dec 2024; status: enrolling by invitation.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06989866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06989866.